In the 64th American Society of Hematology (ASH) Annual Meeting and Exposition 2022, Dr. Johannes Schetelig, on behalf of the Study Alliance Leukemia and the German Cooperative Transplant Study Group, presented his group’s study to prove their hypothesis that salvage chemotherapy before allogeneic h

In the 64th American Society of Hematology (ASH) Annual Meeting and Exposition 2022, Dr. Laura C. Michaelis from the Medical College of Wisconsin, United States (US), and Dr. Kristen O'Dwyer from the University of Rochester Medical Center, US, presented the current ASH recommendations for less inten

There is a highly unmet clinical need for older and medically fit acute myeloid leukemia (AML) patients, dueto resistance to intensive chemotherapy, leading to a poor long-term survival of <20% unless hematopoieticstem cell transplantation (HSCT) is performed.¹ These patients often present with more frequentadverse-genetics and rare successful bridging to allografting.¹ Deoxyribonucleic acid (DNA)-hypomethylating agents (HMAs) are reduced-toxicity treatment options approved for medically non-fitAML patients, but are not curative as monotherapy. Also, the activity of HMAs is found in adverse-geneticsAML.¹ Extended decitabine exposure (10-day) may be a promising alternative with better tolerability thanthe conventional 3+7 induction chemotherapy (IC) regimen in bridging these patients to transplant.¹

Acute myeloid leukemia (AML) is a heterogenous disease characterized by chromosomal variability. Typically, patients with the core binding factor AML (CBF-AML) subtype have a better prognosis than those with cytogenetically normal AML (CN-AML). On the other hand, patients with complex/monosomal kary

Acute myeloid leukemia (AML) therapy planning usually requires stratification of patients based on their age and performance status. Only young and fit patients would be eligible for intensive chemotherapy, limiting older unfit patients to lower intensity treatment which would usually result in lower long-term survival rate.¹

The risk of death was reduced by 34% among participants receiving the combination of venetoclax and azacitidine (OS HR=0.66, p<0.001); the median overall survival was 14.7 months for venetoclax combination vs. 9.6 months for placebo Among patients on venetoclax and azacitidine, 36.7%